| Adherence to the CDK 4/6 Inhibitor Palbociclib and Omission of Dose Management Supported by Pharmacometric Modelling as Part of the OpTAT Study | Cancers |  | | 2023 | 177 | 106 |
|
| Population pharmacokinetics of palbociclib and its correlation with clinical efficacy and safety in patients with advanced breast cancer | Pharmaceutics | | | 2022 | 134 | 228 |
|
